About BioAdvance
BioAdvance is a venture capital firm founded in 2002. It is primarily based out of Radnor, United States. As of May 2026, BioAdvance is an active investor, having invested in 78 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series A round of Latus Overall, BioAdvance portfolio has seen 3 IPOs and 15 acquisitions including key companies like WellSheet, Keriton and Immunome. A lot of funds co-invest with BioAdvance, with names like Novartis Venture Fund sharing a substantial percentage of its portfolio. BioAdvance has team of 8 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio Soonicorns
Deals in last 12 months
BioAdvance's List of Top Investments
BioAdvance has a portfolio of 78 companies. Their most notable investments are in Keriton and VESTECK.Their portfolio spans across United States and United Kingdom. They have invested in Life Sciences, HealthTech, High Tech and 3 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by BioAdvance:Developer of therapeutics to treat rare diseases. Their lead program RAPATANE is a novel proprietary formulation of sirolimus for topical application for Pachyonychia Congenita- an autosomal dominant skin disorder that affects skin and nails. This disease has got an Orphan designation by the FDA & EMEA and the company has received an FDA Orphan Drug grant for development of their sirolimus-based treatment for the same.
Key facts about Palvella Therapeutics
- Founded Year: 2015
- Location: Wayne (United States)
- Stage: Series D
- Total Funding till date: $65.4M
- Employee Count: 43 as on Jun 30, 2026
- Investors: Adams Street Partners, BVF Partners and 11 Others
- Latest Funding Round: Series D, Dec 12, 2024, $*****
- Highlight: Editors' Pick
2. WellSheet
Provider of a web application for care quality and productivity improvement. The caregivers can view the patient’s timeline of visits and information updates, pertinent lab values, list of medications, risks that may affect care, and the team working with the patient. The platform also provides data visualizations to conduct a more detailed analysis.
Key facts about WellSheet
- Founded Year: 2015
- Location: New York City (United States)
- Stage: Acquired
- Total Funding till date: $9.94M
- Employee Count: 14 as on Jun 30, 2026
- Investors: REDO Ventures, BioAdvance and 8 Others
- Latest Funding Round: Series A, Sep 06, 2022, $*****
- Highlight: Acquired
3. Keriton
Feeding management platform ensuring safe, efficient care for hospitalized infants and children. This innovative platform, designed by clinicians, streamlines workflows, enhances efficiency, and drives data-driven safety in neonatal and pediatric hospital settings. It optimizes breast milk management, boosts lactation support, and promotes parent engagement. The platform offers multilayered validations for safe feeds, simplifies recipe preparation, and provides real-time analytics with quality metrics. It connects families with care teams, offering updates and secure messaging. The solution is HIPAA-compliant, offers secure EMR integration, and is SOC 2 Type 2 certified. It supports clinical dietitians, lactation consultants, bedside nurses, and parents, ensuring accuracy, reliability, and improved communication. This comprehensive, cloud-based SaaS solution is built with clinicians and evolves with your needs, offering robust training and technical support.
Key facts about Keriton
- Founded Year: 2016
- Location: Philadelphia (United States)
- Stage: Acquired
- Total Funding till date: $2.11M
- Employee Count: 25 as on Jun 30, 2026
- Investors: Penn Medicine, BioAdvance and 7 Others
- Latest Funding Round: Seed, Sep 21, 2018, $*****
- Highlight: Acquired
4. Immunome
Developer of antibody-based therapeutics for treating cancer. Its lead oncology discovery program targets IL-38, a lesser-known member of the IL-1 family of cytokines. It allows tumors to evade the immune system response efforts. It utilizes B-cells from early-stage cancer patients and by using its fusion cell technology, RealMab, converts these B-cells into stable hybridomas that express thousands of affinity-matured monoclonal antibodies (mAbs) enriched for functional tumor antigen binding.
Key facts about Immunome
- Founded Year: 2008
- Location: Philadelphia (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $54.2M
- Employee Count: 256 as on Jun 30, 2026
- Investors: Evolution VC Partners, BioAdvance and 4 Others
- Latest Funding Round: Post IPO, Apr 26, 2021, $*****
- Highlight: Public
5. Allevi
3D bioprinting solutions: bioprinters, bioinks, and software for tissue engineering. They provide simplified bioprinting with versatile desktop 3D bioprinters, diverse bioinks, and user-friendly software. Their technology empowers researchers to design and engineer 3D tissues for applications like regenerative medicine, drug discovery, and disease modeling. They offer tools for extrusion bioprinting, precision printing, and creating complex geometries. Their products include bioprinters, bioinks for various tissues (liver, heart, bone, etc.), and essential reagents. They support the scientific community with resources like bioprinting protocols, blogs, webinars, and application notes. They also have an online shop with products like nozzles, alginate, photoinitiators, and calcium chloride. They offer login access for software, services, and support. They are focused on advancing bioprinting and regenerative medicine.
Key facts about Allevi
- Founded Year: 2014
- Location: Philadelphia (United States)
- Stage: Acquired
- Total Funding till date: $2.33M
- Employee Count: 16 as on Jul 01, 2024
- Investors: Sand Hill Venture Capital, FundersClub and 15 Others
- Latest Funding Round: Seed, Oct 30, 2019, $*****
- Highlight: Acquired
BioAdvance's Year-on-Year Investment Trends
BioAdvance has invested in 78 companies over the last 22 years, with an average of 2 new investments annually in the last 10 years. As of May 2026, it has made 1 investment in this year. Its most recent first time investment was in Latus and most recent follow-on round was in Kayothera.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
2022 | 3 | 3 | 6 |
2021 | 1 | 1 | 2 |
2020 | 2 | 3 | 5 |
2019 | 3 | 1 | 4 |
2018 | 2 | 1 | 3 |
2017 | 7 | 1 | 8 |
BioAdvance's Investments by Stage
BioAdvance has made 32 investments in Seed stage with an average round size of $1.44M, 12 investments in Series A stage with an average round size of $20.4M and 6 investments in Series B stage with an average round size of $14.7M.Stage of entry | No. of Investments |
|---|---|
Seed | 32 |
Series A | 12 |
Series B | 6 |
Note: We have considered here, only first round of investments
BioAdvance's Investments by Sector
BioAdvance has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Sustainability Tech and High Tech. Notably, it has invested in 67 Tech companies, 60 Enterprise (B2B) companies, 26 Software companies and at least 12 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 36 |
HealthTech | 14 |
Enterprise Applications | 11 |
Sustainability Tech | 7 |
High Tech | 5 |
Others | 7 |
Note: We have considered here, only first round of investments
BioAdvance's Investments by Geography
BioAdvance has made most investments in United States (50), followed by United Kingdom where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 50 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
BioAdvance's recent investments
BioAdvance has made 1 investments in 2026 so far - Latus.Here are the most recent investments by BioAdvance:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 04, 2026 | United States | Series A | 8730 | [+6] | |
Oct 29, 2024 | United States | Seed | 1395 | ||
Jul 19, 2023 | United States | Grant (prize money) | 8241 | [+3] | |
Dec 30, 2022 | United States | Series D | 2426 | [+5] | |
Dec 12, 2022 | United States | Seed | 2646 |
IPOs and Publicly Listed companies in BioAdvance's Portfolio
3 of BioAdvance's portfolio companies have become public. Immunome got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2020 at marketcap of $120M and Annovis got listed on the New York Stock Exchange (NYSE) at marketcap of $39.1M.Here are BioAdvance's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 02, 2020 | May 24, 2010 | Seed | 9569 | |
Jan 29, 2020 | Jun 02, 2010 | Seed | 7022 | |
May 20, 2014 | Oct 01, 2013 | Series A | 5672 |
Acquired companies in BioAdvance's Portfolio
15 companies from BioAdvance's portfolio have been acquired. The most recent acquisition was WellSheet in Jun 2026 by Elsevier for $*****.Here are BioAdvance's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 08, 2026 | Oct 27, 2017 | Seed | 1721 | |
Jan 28, 2026 | Feb 16, 2017 | Seed | 5779 | |
May 21, 2025 | Dec 20, 2018 | Series B | 3832 | |
Sep 20, 2022 | Aug 14, 2019 | Series A | 5105 | |
May 06, 2021 | - | - | 7252 |
Team profile of BioAdvance
BioAdvance has a team of 8 members including 3 Partners, 2 Venture Partners and 2 Principals located in United States. BioAdvance's team sits on the board of 1 company.Here is a list of all team members in BioAdvance:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Vero Beach | - | ||
Partner | Princeton | |||
Partner | Wayne | - | ||
Venture Partner | United States | - | - | |
Venture Partner | United States | - | - | |
Principal | - | - | ||
Principal | - | - |
Co-investors of BioAdvance
Over the past 22 years, 162 investors have co-invested in BioAdvance's portfolio companies. This includes funds and angels.
- Invested before BioAdvance: HHS, Ben Franklin Technology Partners and 25 others have invested in rounds before BioAdvance. There are 5 companies where HHS has invested before BioAdvance and 4 companies where Ben Franklin Technology Partners has invested before BioAdvance.
- Top Co-investors of BioAdvance: 56 investors entered a company along with BioAdvance. These include investors like Novartis Venture Fund (3 companies).
- Invested after BioAdvance: A total of 79 investors have invested in BioAdvance's portfolio after their investments. Top Investors include HHS (11 companies), Robin Hood Ventures (2 companies) and NIH (2 companies).
Recent News related to BioAdvance
•
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 DiseaseBusiness Wire•Apr 28, 2026•Latus, Modi Ventures, Hatch BioFund, Gaingels and 4 others
•
•
•
•
•
Palvella Therapeutics Raises Up To $37.7M Series D FinancingFinSMEs•Jan 09, 2023•Palvella Therapeutics, Petrichor, Gore Range Capital, Samsara BioCapital and 6 others
•
•
BioAdvance says it added 8 portfolio companies in 'record-breaking' investment yearThe Business Journals•Nov 14, 2022•BioAdvance
•
•
